18:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

FDA approves Ortho Dermatologics' tretinoin lotion for acne

The Ortho Dermatologics unit of Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) said FDA approved Altreno tretinoin 0.05% topical lotion to treat acne vulgaris in patients ages nine and older. Ortho Dermatologics said the product is...
17:45 , May 11, 2018 |  BC Week In Review  |  Clinical News

Sol-Gel's acne candidate meets in Phase II

In February, Sol-Gel Technologies Ltd. (NASDAQ:SLGL) said once-daily low- and high-dose topical cream TWIN (S6G5T) both met the three co-primary endpoints compared with vehicle in a Phase II trial in 726 patients with acne. Data...
20:36 , Feb 2, 2018 |  BC Week In Review  |  Financial News

Sol-Gel raises $75M in IPO

Dermatology company Sol-Gel Technologies Ltd. (NASDAQ:SLGL) raised $75 million after market hours on Jan. 31 through the sale of 6.3 million shares at $12 in an IPO. The offering was underwritten by Jefferies, BMO Capital...
02:29 , Feb 1, 2018 |  BC Extra  |  Financial News

Sol-Gel raises $75M in IPO

Dermatology company Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was up $1.64 (14%) to $13.64 on Thursday after raising $75 million late Wednesday through the sale of 6.3 million shares at $12 in an IPO. The offering was...
19:35 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA approved Trisenox arsenic trioxide plus tretinoin to treat adults with newly diagnosed low-risk acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or...
06:23 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

FDA accepts Valeant's tretinoin lotion NDA for acne

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said FDA accepted for a review an NDA for Altreno tretinoin 0.05% (IDP-121) to treat acne. The PDUFA date is Aug. 27. Altreno is a topical tretinoin in a...
23:20 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

IMG-7289: Ph I/II started

Imago began an open-label, Australian Phase I/II trial to evaluate oral IMG-7289 with and without tretinoin in 30 patients. The dose-escalation Phase I portion will identify the selected dose of IMG-7289 for the dose-expansion Phase...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

GlaxoSmithKline, Almirall deal

GlaxoSmithKline granted Almirall rights to develop and commercialize Veltin Gel clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin in Austria, the Czech Republic, Italy, the Netherlands, Poland,...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Tretinoin gel: Phase II data

An Australian and New Zealand Phase II trial in 53 patients with mild to moderate acne vulgaris showed that once-daily topical TPM/Tretinoin gel led to a mean reduction in acne lesions from baseline to week...
07:00 , Aug 11, 2014 |  BioCentury  |  Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...